Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

EMA starts review of Gilead’s Zydelig on ‘serious’ safety concerns

Trials of the leukaemia treatment have been halted while the investigation is underway

- PMLiVE

Harnessing commercial innovation

Novo Nordisk’s Christian Kanstrup on meeting challenges head-on and preparing for an era of launches

- PMLiVE

Abbott diabetes sensor wins European CE mark

FreeStyle Libre system gains kitemark

- PMLiVE

Pharma’s reputation rises, but pricing still a sore point

Patient group survey sees the industry's corporate reputation increase

AZ and Roche fund PatientsLikeMe cancer patient outcomes study

The online patient network's cancer experience research will also involve M2Gen

- PMLiVE

Women’s well-being needs are broader than health

Merck event hears how women’s and government priorities are often mismatched

Sanofi reception

Sanofi’s sarilumab beats Humira in head-to-head trial

Rheumatoid arthritis candidate was more effective than AbbVie's market-leader

- PMLiVE

McCann Health promotes Charlie Buckwell to president EMEA

And Michel Nakache becomes head of global clients

- PMLiVE

Insights from the Authenticity Gap research

Successful companies align their brand with their reputation

Why health psychology should inform pharma strategy

In the March 2016 edition of PME, Ella Nuttall (Health Psychology Specialist at Lucid Group) discusses why pharma should look to health psychology and adopt a behaviour-change strategy to inform...

Lucid Group Communications Limited

Shire Basingstoke

Shire launches long-acting ADHD drug Intuniv in UK

Also plans to launch the once-daily treatment in Japan later this year

ABPI London offices

UK pharma’s contribution to NHS hits £1bn mark

ABPI says local access to new treatments still not universal despite drug rebates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links